Enhancement of Antiviral CD8+ T-Cell Responses and Complete Remission of Metastatic Melanoma in an HIV-1-Infected Subject Treated with Pembrolizumab

Antigen Production After Latency Reversal and Expression of Inhibitory Receptors in CD8+ T Cells Limit the Killing of HIV-1 Reactivated Cells

(2019) Alba Ruiz et al.   Frontiers in Immunology

Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer

(2019) Michael R. Cook et al.   JAMA Oncology

PD-1 blockade potentiates HIV latency reversal ex vivo in CD4+ T cells from ART-suppressed individuals

(2019) Rémi Fromentin et al.   Nature Communications

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

(2019) O Hamid et al.   ANNALS OF ONCOLOGY

Phase II study of durvalumab (MEDI4736) in cancer patients HIV-1-infected.

(2019) María González-Cao et al.   JOURNAL OF CLINICAL ONCOLOGY

Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer—A Phase 1 Study

(2019) Thomas S. Uldrick et al.   JAMA Oncology

Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection

(2018) E P Scully et al.   ANNALS OF ONCOLOGY

Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy

(2017) Cynthia L. Gay et al.   JOURNAL OF INFECTIOUS DISEASES

Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer

(2017) Stefanie Aust et al.   Scientific Reports

Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: Receptors, functions, and roles in diseases

(2016) Mübeccel Akdis et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

PD-1+ and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals

(2016) Riddhima Banga et al.   NATURE MEDICINE

CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART

(2016) Rémi Fromentin et al.   PLoS Pathogens

Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma

(2015) Fiona Wightman et al.   AIDS

Establishment and Replenishment of the Viral Reservoir in Perinatally HIV-1-infected Children Initiating Very Early Antiretroviral Therapy

(2015) Marta Martínez-Bonet et al.   CLINICAL INFECTIOUS DISEASES

Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway

(2015) Kim C. Ohaegbulam et al.   TRENDS IN MOLECULAR MEDICINE

Effect of lithium on HIV-1 expression and proviral reservoir size in the CD4+ T cells of antiretroviral therapy suppressed patients

(2014) Maria C. Puertas et al.   AIDS

Programmed Death-1 Is a Marker for Abnormal Distribution of Naive/Memory T Cell Subsets in HIV-1 Infection

(2013) G. Breton et al.   JOURNAL OF IMMUNOLOGY

Cell-Based Measures of Viral Persistence Are Associated With Immune Activation and Programmed Cell Death Protein 1 (PD-1)–Expressing CD4+ T cells

(2012) Hiroyu Hatano et al.   JOURNAL OF INFECTIOUS DISEASES

Shock and kill

(2012) Steven G. Deeks   NATURE

SPICE: Exploration and analysis of post-cytometric complex multivariate datasets

(2011) Mario Roederer et al.   CYTOMETRY PART A

Standardization and performance evaluation of “modified” and “ultrasensitive” versions of the Abbott RealTime HIV-1 assay, adapted to quantify minimal residual viremia

(2011) Alessandra Amendola et al.   JOURNAL OF CLINICAL VIROLOGY

Purging the HIV-1 reservoir through the disruption of the PD-1 pathway

(2010) S DaFonseca et al.   Journal of the International AIDS Society

Enhancing SIV-specific immunity in vivo by PD-1 blockade

(2008) Vijayakumar Velu et al.   NATURE